Eagle Health Investments’s Dianthus Therapeutics DNTH Stock Holding History

Eagle Health Investments’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.8M	Buy	+131,344	New	+$11.5M	2.12%	20

Other funds holding DNTH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Eagle Health Investments's DNTH Position: Q2 2026 in Review

Eagle Health Investments opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 131,344 shares worth $12.8M. The stake represents 2.12% of the portfolio and ranks #20 among its holdings.

82 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Eagle Health Investments held 131,344 shares of Dianthus Therapeutics worth $12.8M as of Q2 2026.
Dianthus Therapeutics was a new Eagle Health Investments position in Q2 2026.
Dianthus Therapeutics made up 2.12% of Eagle Health Investments's portfolio in Q2 2026, its #20 holding.
82 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Eagle Health Investments's 13F filing for Q2 2026, filed 10 Aug 2026.